Overview

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults

Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of CVnCoV at different dose levels.
Phase:
Phase 1
Details
Lead Sponsor:
CureVac AG
Collaborators:
Coalition for Epidemic Preparedness Innovations
Coalition for Epidemic Preparedness Innovations (CEPI)